Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial

Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying...

Full description

Saved in:
Bibliographic Details
Published inBlood Vol. 138; no. Supplement 1; p. 3603
Main Authors Breccia, Massimo, Luciano, Luigia, Annunziata, Mario, Attolico, Imma, Malato, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Scortechini, Anna Rita, Cascavilla, Nicola, Di Renzo, Nicola, Impera, Stefana, Lunghi, Monia, Santoro, Marco, Castagnetti, Fausto, Maggi, Alessandro, Sargentini, Valeria, Piciocchi, Alfonso, Galimberti, Claudia, Iurlo, Alessandra
Format Journal Article
LanguageEnglish
Published Elsevier Inc 23.11.2021
Online AccessGet full text

Cover

Loading…
Abstract Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib. Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented. Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available. At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%). Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation. Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study. [Display omitted] Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau.
AbstractList Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib. Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented. Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available. At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%). Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation. Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study. [Display omitted] Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau.
Abstract Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia, or those carrying the T315I mutation. Ponatinib has been commercially available since January 2015, yet there is a paucity of data on its use in the real-world setting. The goal of the Observational study of Iclusig ® (ponatinib) Treatment in patients with CML in Italy (OITI) was to evaluate treatment patterns and outcomes, including safety and efficacy, in patients with CML treated in Italy since the approval of ponatinib. Methods. This noninterventional study included patients aged ≥18 years with CP, AP, or BP CML who initiated ponatinib treatment in routine clinical practice across 26 Italian centers (academic and hospital settings). The study population comprised a prospective cohort, including patients who started treatment with ponatinib after site activation during the 12-month enrollment period; a retrospective cohort, including patients who started treatment with ponatinib but died or were lost to follow-up prior to site activation; and a retrospective/prospective cohort, including patients who started treatment with ponatinib prior to site activation and were still on treatment or in follow-up at the end of the study. Demographic, efficacy, and safety data were collected from patient medical charts at study entry and routine visits. The primary endpoint was the complete cytogenetic response (CCyR) rate in CP CML patients 6 months after starting ponatinib. In the absence of cytogenetic evaluation, molecular assessment was used, considering patients in MR2 or better to be in CCyR. Here, the primary analysis of all evaluable patients for the primary endpoint (median follow-up, 23.7 months [range, 1.3-70.8]) is presented. Results. A total of 119 patients (110 CP, 6 AP, and 3 BP CML) were analyzed. Fifty-nine (49.6%) received ponatinib in second-line (2L), 41 (34.4%) in 3L, and 19 (16.0%) in ≥4L. Prior cardiovascular disease/hypertension was recorded in 56 (47.1%) patients. Median age at ponatinib start was 60 years (range, 19-93). Of 68 evaluated patients, 24 (35.3%) had a confirmed ABL1 mutation, including 7 (10.3%) with the T315I mutation. Starting doses of ponatinib were 45 mg (37.0%), 30 mg (41.2%), or 15 mg (21.8%). Median treatment duration was 22.8 months (range, 1.4-73.6). At baseline, 56 patients with CP CML had less than CCyR and 53 were in CCyR. For 1 patient, assessment was not available. At 6 months, 80/107 evaluable patients with CP CML were in CCyR; 29/56 (51.8%) achieved and 50/50 (100%) maintained CCyR compared to baseline, respectively. For 1 patient, baseline data were unavailable. Additionally, 37 (34.6%) and 19 (17.8%) patients with CP CML achieved a major molecular response (MMR; MR3) and a deep molecular response (MR4-MR5), respectively (Table 1). Progression-free survival rates estimated for patients with CP CML at 12 and 24 months were 92.6% (95% CI, 87.8-97.7%) and 84.6% (95% CI, 77.2-92.6%), respectively. Corresponding overall survival rates were 95.4% (95% CI, 91.6-99.4%), and 88.4% (95% CI, 81.7-95.7%). Seventy-one (59.7%) patients had treatment-related adverse events (AEs), most commonly rash, hypertension (Grade 1-2), and thrombocytopenia (Grade 3). Treatment-related arterial occlusive events occurred in 2 (1.7%) patients. Dose modifications occurred in 77 patients: 37.1% were due to AEs, 13.5% were reductions after at least major cytogenetic response, 10.6% were increases due to lack of efficacy, 1.7% were medical decisions, and 37.1% were for other reasons. Thirty-three patients discontinued ponatinib due to AEs (33.3%), medical decisions (24.2%), and other reasons (42.4%), such as death, progression, and hematopoietic stem cell transplantation. Conclusions. This observational study demonstrates that ponatinib has a favorable efficacy and safety profile in patients with CML treated in standard clinical practice. By 6 months, 74.8% of evaluable patients were in CCyR and 52.3% achieved at least MMR. Further, the probability of survival at 2 years was >88%. No new safety signals emerged with ponatinib treatment compared to prior studies. The early use of ponatinib and careful dose selection appear key to the safety and efficacy outcomes observed in this real-world study. Figure 1 Figure 1. Disclosures Breccia: Abbvie: Honoraria; Bristol Myers Squibb/Celgene: Honoraria; Incyte: Honoraria; Novartis: Honoraria; Pfizer: Honoraria. Abruzzese: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Bonifacio: Pfizer: Honoraria; Amgen: Honoraria; Bristol Myers Squibb: Honoraria; Novartis: Honoraria. Castagnetti: Novartis: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria. Galimberti: Inctye Bioscience Italy Srl: Current Employment. Iurlo: Incyte: Speakers Bureau; Novartis: Speakers Bureau; Pfizer: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau.
Author Scortechini, Anna Rita
Lunghi, Monia
Attolico, Imma
Di Renzo, Nicola
Piciocchi, Alfonso
Impera, Stefana
Abruzzese, Elisabetta
Castagnetti, Fausto
Sargentini, Valeria
Malato, Alessandra
Cascavilla, Nicola
Maggi, Alessandro
Santoro, Marco
Galimberti, Claudia
Iurlo, Alessandra
Bonifacio, Massimiliano
Annunziata, Mario
Luciano, Luigia
Breccia, Massimo
Author_xml – sequence: 1
  givenname: Massimo
  surname: Breccia
  fullname: Breccia, Massimo
  organization: Division of Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy
– sequence: 2
  givenname: Luigia
  surname: Luciano
  fullname: Luciano, Luigia
  organization: Hematology Unit, Federico II University of Naples, Napoli, Italy
– sequence: 3
  givenname: Mario
  surname: Annunziata
  fullname: Annunziata, Mario
  organization: Hematology Unit, Azienda Ospedaliera Cardarelli, Naples, Italy
– sequence: 4
  givenname: Imma
  surname: Attolico
  fullname: Attolico, Imma
  organization: Haematology and Transplants Unit, University of Bari, Bari, Italy
– sequence: 5
  givenname: Alessandra
  surname: Malato
  fullname: Malato, Alessandra
  organization: Department of Hematology, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy
– sequence: 6
  givenname: Elisabetta
  surname: Abruzzese
  fullname: Abruzzese, Elisabetta
  organization: Hematology, S. Eugenio Hospital, Tor Vergata University, Rome, Italy
– sequence: 7
  givenname: Massimiliano
  surname: Bonifacio
  fullname: Bonifacio, Massimiliano
  organization: Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
– sequence: 8
  givenname: Anna Rita
  surname: Scortechini
  fullname: Scortechini, Anna Rita
  organization: Division of Hematology, Department of Molecular and Clinical Sciences, Polytechnic University of Marche, Ancona, Italy
– sequence: 9
  givenname: Nicola
  surname: Cascavilla
  fullname: Cascavilla, Nicola
  organization: Division of Hematology, IRCCS Casa Sollievo Della Sofferenza Hospital, San Giovanni Rotondo, Italy
– sequence: 10
  givenname: Nicola
  surname: Di Renzo
  fullname: Di Renzo, Nicola
  organization: Department of Hematology and Stem Cell Transplant, Presidio Ospedaliero Vito Fazzi, Lecce, Italy
– sequence: 11
  givenname: Stefana
  surname: Impera
  fullname: Impera, Stefana
  organization: Division of Hematology, ARNAS Garibaldi, Catania, Italy
– sequence: 12
  givenname: Monia
  surname: Lunghi
  fullname: Lunghi, Monia
  organization: Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
– sequence: 13
  givenname: Marco
  surname: Santoro
  fullname: Santoro, Marco
  organization: Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy
– sequence: 14
  givenname: Fausto
  surname: Castagnetti
  fullname: Castagnetti, Fausto
  organization: Istituto di Ematologia “Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, University of Bologna, Bologna, Italy
– sequence: 15
  givenname: Alessandro
  surname: Maggi
  fullname: Maggi, Alessandro
  organization: Division of Hematology, Hospital “S.G. Moscati”, Taranto, Italy
– sequence: 16
  givenname: Valeria
  surname: Sargentini
  fullname: Sargentini, Valeria
  organization: GIMEMA Foundation, Rome, Italy
– sequence: 17
  givenname: Alfonso
  surname: Piciocchi
  fullname: Piciocchi, Alfonso
  organization: GIMEMA Foundation, Rome, Italy
– sequence: 18
  givenname: Claudia
  surname: Galimberti
  fullname: Galimberti, Claudia
  organization: Medical Department, Incyte Biosciences Italy S.R.L, Milan, Italy
– sequence: 19
  givenname: Alessandra
  surname: Iurlo
  fullname: Iurlo, Alessandra
  organization: Hematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
BookMark eNp9kMlOwzAURS1UJNrCB7DzBxDwlAlWVcRQqVUr6D7yFNUoxJXtFuU_-GAcwoIVq_d0pXvfu2cGJp3tNADXGN1iXJA70VqrEoIITjDLMC3PwBSnpEgQImgCpgihLGFlji_AzPt3hDCjJJ2Cr_WxDUbqLmh3A7fO-oOWwZw05J2Crzr8UTbCa3fiwdiOt7Cye-sCfAtH1UPbwG1Ug-mMgKaD27jGTA8_TdjDar0axGXgbX8fj5gP7nq4iCm9N34wh32MN8HAnTO8vQTnDW-9vvqdc7B7etxVL8lq87ysFqtE4iItE6bzsuAi41qlWjBJJWMiww1WhJIszxHPedYIoRDLkZQ6y6lghGBMC5ZSRucAj7EylvRON_VhfK3GqB6o1j9U64FqPVKNnofRo-NfJ6Nd7WVsKrUyLmKqlTX_uL8BJBOD3w
CitedBy_id crossref_primary_10_1007_s11899_022_00683_3
crossref_primary_10_3390_hemato4030017
crossref_primary_10_1080_17474086_2023_2234084
crossref_primary_10_1007_s00277_023_05168_8
crossref_primary_10_1016_j_clml_2023_03_004
crossref_primary_10_1186_s13045_022_01309_0
ContentType Journal Article
Copyright 2021 American Society of Hematology
Copyright_xml – notice: 2021 American Society of Hematology
DBID AAYXX
CITATION
DOI 10.1182/blood-2021-146139
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 3603
ExternalDocumentID 10_1182_blood_2021_146139
S0006497121055270
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6J9
AAEDW
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
AHPSJ
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
0SF
AALRI
AAYXX
ADVLN
AFETI
AITUG
AKRWK
CITATION
H13
ID FETCH-LOGICAL-c1859-4e798ab6aed5eb4c3c44b61f1d2326770a7a6fbbd0470cce673b422113845343
IEDL.DBID ABVKL
ISSN 0006-4971
IngestDate Thu Sep 12 16:41:59 EDT 2024
Fri Feb 23 02:41:45 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement 1
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1859-4e798ab6aed5eb4c3c44b61f1d2326770a7a6fbbd0470cce673b422113845343
OpenAccessLink https://doi.org/10.1182/blood-2021-146139
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_2021_146139
elsevier_sciencedirect_doi_10_1182_blood_2021_146139
PublicationCentury 2000
PublicationDate 2021-11-23
PublicationDateYYYYMMDD 2021-11-23
PublicationDate_xml – month: 11
  year: 2021
  text: 2021-11-23
  day: 23
PublicationDecade 2020
PublicationTitle Blood
PublicationYear 2021
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.4191816
Snippet Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP), accelerated phase...
Abstract Background. Ponatinib is a third-generation tyrosine kinase inhibitor indicated for adults with resistant or intolerant chronic phase (CP),...
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 3603
Title Multicenter, Prospective and Retrospective Observational Cohort Study of Ponatinib in Patients with CML in Italy: Primary Analysis of the Oiti Trial
URI https://dx.doi.org/10.1182/blood-2021-146139
Volume 138
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5REC0XRJdWUB6aQ8UBNdrYceLAbYlAvBa21bbiFtleR82BLNpuD_s_-MHM5IGoVC7cIksjW5mR55vxzHwAX2Mto4Li40A4pjCT0gUmVXGgPVNbS5NKy_mO4U1y_lNd3sV3S5B1vTBcVtne_c2dXt_W7Uq__Zv9h7LkHl9yp0eaJ2DxGDGK21ckoV8y9pXBya-r6-fHBBXJhsiAgmcWaB83CVn3m-pwyXUKTHDNlOH_c08vXM7ZBqy3WBEHzXE-wpKverA5qChOvl_gAdbVm3VavAerJ93Xh6zjcOvB-2H7dL4Jj3WrLddi-tk3HM2mXY8lmmqCP_z8xcqtfc7V0v7Z9DdhdOSKwwVOCxxxwr2sSotlhaNmLusf5IQuZsNrXrwgRL84pk3qSRbYDT5hYcKbeFvOSxyz5X-C8dnpODsPWkqGwJFjJ2V6fZQamxg_ib1VLnJK2UQUYkLILNE6NNokhbWTUOnQOZ_oyJIBCBGRAUQq-gzL1bTyW4ChcmFYpCa0JlbW0pfQzgvprC6ckHYbDjtF5A_NcfM6YEllXmstZ63ljda2QXWqyv-xnpwcw-tiX94mtgNrjcWIQEa7sDyf_fV7BE3mdr81vX14d_U9fQJ3leLh
link.rule.ids 315,783,787,27583,27938,27939,45677
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LTxsxEB4hUEsvFQ0g3p1D1UPVVdZe73rhFlZFoSQQVSnitrIdr7qHblAaDvkf_ODO7ANRqVy4WZZGtjyjmW_G8wD4FGsZFeQfB8LxCDMpXWBSFQfa82hraVJpOd4xvk6GP9X3u_huDbKuFobTKlvd3-j0Wlu3O_32Nfv3Zck1vmROTzV3wOI2YuS3bxAa0OSBbQzOb69GT58JKpLNIANynpmg_dwkZN1vssMl5ynwgGseGf4_8_TM5FxswfsWK-Kguc4HWPNVD7YHFfnJv1f4GevszTos3oM3591qM-tmuPXg7bj9Ot-Gx7rUlnMx_eIrThbzrsYSTTXDH375bOfGPsVq6fxs_oswOnLG4QrnBU444F5WpcWywknTl_UPckAXs_GINy8J0a_O6JC6kwV2jU-YmPAm3pTLEqcs-Tswvfg2zYZBO5IhcGTYiZlen6bGJsbPYm-Vi5xSNhGFmBEyo7cPjTZJYe0sVDp0zic6siQAQkQkAJGKdmG9mld-DzBULgyL1ITWxMpaWgntvJDO6sIJaffhS8eI_L65bl47LKnMa67lzLW84do-qI5V-T_Sk5NheJns4HVkH2FzOB2P8tHl9dUhvGukRwQyOoL15eLBHxNMWdqTVgz_Aur-5No
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicenter%2C+Prospective+and+Retrospective+Observational+Cohort+Study+of+Ponatinib+in+Patients+with+CML+in+Italy%3A+Primary+Analysis+of+the+Oiti+Trial&rft.jtitle=Blood&rft.au=Breccia%2C+Massimo&rft.au=Luciano%2C+Luigia&rft.au=Annunziata%2C+Mario&rft.au=Attolico%2C+Imma&rft.date=2021-11-23&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=138&rft.issue=Supplement+1&rft.spage=3603&rft.epage=3603&rft_id=info:doi/10.1182%2Fblood-2021-146139&rft.externalDBID=n%2Fa&rft.externalDocID=10_1182_blood_2021_146139
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon